Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Unknown 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Thrombocytosis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Meningeal Carcinomatosis 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Hepatitis B, Chronic 1Hepatitis B 1Carcinoma, Hepatocellular 1Brain Neoplasms 1

Interventions

lenvatinib 16Bevacizumab 14sintilimab 10tislelizumab 9apatinib 9regorafenib 6camrelizumab 6donafenib 5atezolizumab 5Immune Checkpoint Inhibitors 4Hepatectomy 4cabozantinib 3Radiosurgery 3Capecitabine 3spartalizumab 2pembrolizumab 2durvalumab 2anlotinib 2Surgical Procedures, Operative 2Specimen Handling 2Oxaliplatin 2Observation 2Magnetic Resonance Spectroscopy 2Injections 2Immunotherapy 2Folfox protocol 2Fecal Microbiota Transplantation 2Electroporation 2Blood Specimen Collection 2ursodoxicoltaurine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma, Hepatocellular × peginterferon alfa-2b × Clear all
NCT07553767 2026-04-28

Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection

Ningbo No.2 Hospital

Phase EARLY_PHASE1 Not yet recruiting
156 enrolled
Gastrointestinal

Hepatitis B, Carcinoma, Hepatocellular, Hepatitis B, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡